Trankimazin 2mg U94s Pfizer

Trankimazin 2mg U94s Pfizer

Trankimazin 2mg  u94 pfizer belongs to the group of medicine call translquilizers ( anxiolytics) derive from benzodiazepine.

Xanax is indicate for the short-term treatment of moderate or severe anxiety states. And anxiety associate with depression. It is only indicate when the disorder is severe.  Disabling or subjecting the individual to extreme distress.

Also , Xanax should not be use to treat short-term mild anxiety, such as anxiety or tension associated with the stress of everyday life. As the efficacy of Xanax in depression.And in phobic or obsessional states has yet to be established. Specific treatment may have to be consider.

Trankimazin Tablets are indicate for the treatment of panic disorder, with or without agoraphobia.

This claim is support on the basis of two positive studies with Trankimazin conduct in patients whose diagnoses correspond closely to the DSM-III-R/IV criteria for panic disorder.

The longer-term efficacy of Trankimazin 2mg U94s Pfizer has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks, should periodically reassess the usefulness of the drug for the individual patient.

Trankimazin is indicat for the short-term treatment of moderate or severe anxiety states and anxiety associate with depression. It is only indicate when the disorder is severe, disabling or subjecting the individual to extreme distress.

Uses of Trankimazin 2mg

Trankimazin should not be use to treat short-term mild anxiety, such as anxiety or tension associate with the stress of everyday life. As the efficacy of Trankimazin in depression and in phobic or obsessional states has yet to be establish, specific treatment may have to be consider.

Demonstrations of the effectiveness of Trankimazin by systematic clinical study are limit to 4 months, in duration for generalize anxiety disorder and 4 to 10 weeks duration for panic disorder.

However, patients with panic disorder have be treat on an open basis for up to 8 months without apparent loss of benefit.